Skip to main content
PIQRAY header image

Patients with a PIK3CA Mutation Face a Poor Prognosis1

PIK3CA is the most commonly mutated gene in HR+/HER2- aBC2

 

Patients with a PIK3CA mutation can have:

PIK3CA mutation prognosis statistics

mPFS, median progression-free survival.

References: 1. Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386 2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. 3. Data on file. Novartis Pharmaceuticals Corp; 2021. 4. Mollon LE, Anderson EJ, Dean JL, et al. A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR+/HER2- metastatic breast cancer. Clin Breast Cancer. 2020;20(3):e232-e243.